Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With SHR-1210 in Resectable NSCLC
NCT04133337Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Nov 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Sichuan Cancer Hospital. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04133337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04133337.